Holen Sie sich die Stockscreener-App
0.9405
5.77%
0.0514
Handel nachbörslich:
.94
-0.0005
-0.05%
Schlusskurs vom Vortag:
$0.8891
Offen:
$0.91
24-Stunden-Volumen:
370.77K
Relative Volume:
1.42
Marktkapitalisierung:
$118.79M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-70.78M
KGV:
-1.6795
EPS:
-0.56
Netto-Cashflow:
$-61.27M
1W Leistung:
+8.59%
1M Leistung:
+30.48%
6M Leistung:
+20.24%
1J Leistung:
-66.65%
1-Tages-Spanne:
$0.8399
$0.977
1-Wochen-Bereich:
$0.8197
$0.977
52-Wochen-Spanne:
$0.62
$3.026
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Firmenname
Nautilus Biotechnology Inc
Sektor
Branche
Telefon
206-333-2001
Adresse
2701 EASTLAKE AVE EAST, SEATTLE
Vergleichen Sie NAUT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
0.9405 | 112.30M | 0 | -70.78M | -61.27M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-05 | Herabstufung | Goldman | Neutral → Sell |
| 2024-06-27 | Eingeleitet | Guggenheim | Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2022-01-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-02 | Eingeleitet | Cowen | Outperform |
| 2021-08-04 | Eingeleitet | Goldman | Neutral |
| 2021-07-13 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Nautilus Biotechnology Inc Aktie (NAUT) Neueste Nachrichten
Nautilus Biotechnology Inc.’s volatility index tracking explained2025 Trading Recap & Free Daily Entry Point Trade Alerts - newser.com
Why Nautilus Biotechnology Inc. stock is recommended by analystsPortfolio Performance Report & Verified Chart Pattern Signals - newser.com
Earnings visualization tools for Nautilus Biotechnology Inc.Rate Cut & Technical Pattern Recognition Alerts - newser.com
How to recover losses in Nautilus Biotechnology Inc. stockJuly 2025 Selloffs & Risk Controlled Daily Plans - newser.com
Will Nautilus Biotechnology Inc. stock outperform value stocksMarket Trend Report & AI Optimized Trading Strategy Guides - newser.com
How Nautilus Biotechnology Inc. stock performs in rate cut cyclesM&A Rumor & Fast Entry High Yield Stock Tips - newser.com
Can Nautilus Biotechnology Inc. stock weather global recessionJobs Report & Precise Swing Trade Alerts - newser.com
Published on: 2025-10-13 09:25:11 - newser.com
Strategies to average down on Nautilus Biotechnology Inc.Quarterly Trade Summary & Fast Moving Stock Watchlists - newser.com
Weiss Ratings Reaffirms Sell (D-) Rating for Nautilus Biotechnology (NASDAQ:NAUT) - MarketBeat
Will Nautilus Biotechnology Inc. price bounce be sustainableJuly 2025 Fed Impact & Accurate Buy Signal Notifications - newser.com
Should you hold or exit Nautilus Biotechnology Inc. now2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
Live market analysis of Nautilus Biotechnology Inc.Market Trend Review & Reliable Entry Point Alerts - newser.com
Published on: 2025-10-09 04:18:13 - newser.com
Will Nautilus Biotechnology Inc. see short term momentumFed Meeting & Reliable Price Action Trade Plans - newser.com
Is Nautilus Biotechnology Inc a good long term investmentMarket Entry Points & Smart Beta Strategies That Actually Work - earlytimes.in
Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025 - GlobeNewswire
Nautilus Biotechnology, Inc. to Announce Third Quarter 2025 Financial Results on October 28, 2025 - Quiver Quantitative
Nautilus Biotechnology to Participate in Upcoming September Investor Conferences - 富途牛牛
What institutional flow reveals about Nautilus Biotechnology Inc.2025 Institutional Moves & Community Consensus Picks - newser.com
Nautilus Biotechnology Inc. recovery potential after sell offJuly 2025 Fed Impact & Free Community Supported Trade Ideas - newser.com
Is now a turning point for Nautilus Biotechnology Inc.July 2025 Catalysts & High Accuracy Swing Trade Signals - newser.com
How sentiment analysis helps forecast Nautilus Biotechnology Inc.Weekly Stock Summary & Verified Entry Point Signals - newser.com
Nautilus Biotechnology Inc. stock daily chart insightsWeekly Profit Summary & Long Hold Capital Preservation Tips - newser.com
Detecting price anomalies in Nautilus Biotechnology Inc. with AI2025 Top Gainers & Fast Gaining Stock Reports - newser.com
Analyzing Nautilus Biotechnology Inc. with multi timeframe chartsJuly 2025 Opening Moves & Intraday High Probability Alerts - newser.com
What analysts say about Nautilus Biotechnology Inc stockFlag and Pennant Patterns & Exceptional Growth Investment - earlytimes.in
What drives Nautilus Biotechnology Inc stock priceVWAP Trading Strategies & Invest Now – Opportunity Window Closing - earlytimes.in
Goldman Sachs Group Inc. Has $148,000 Stock Position in Nautilus Biotechnology, Inc. $NAUT - Defense World
Finanzdaten der Nautilus Biotechnology Inc-Aktie (NAUT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nautilus Biotechnology Inc-Aktie (NAUT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Patel Sujal M | CEO, President, and Secretary |
Sep 08 '25 |
Buy |
0.68 |
83,500 |
57,031 |
10,341,721 |
| Murphy Matthew B. | General Counsel |
Sep 04 '25 |
Buy |
0.64 |
20,000 |
12,858 |
74,140 |
| Mowry Anna | CFO and Treasurer |
May 29 '25 |
Buy |
0.77 |
15,000 |
11,488 |
83,000 |
| Mallick Parag | Chief Scientist |
May 08 '25 |
Buy |
0.73 |
12,000 |
8,788 |
20,491,892 |
| Mallick Parag | Chief Scientist |
May 12 '25 |
Buy |
0.73 |
1,500 |
1,098 |
20,493,392 |
| Patel Sujal M | CEO, President, and Secretary |
Mar 19 '25 |
Buy |
0.99 |
53,300 |
53,028 |
10,117,788 |
| Patel Sujal M | CEO, President, and Secretary |
Mar 20 '25 |
Buy |
1.00 |
23,933 |
23,890 |
10,141,721 |
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):